BridgeBio Pharma, Inc.
infigratinib
achondroplasia
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on infigratinib for achondroplasia is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Depleter for ATTR-CM Development candidate nomination Submit IND to the FDA in 2027”